Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
The FDA greenlighted Bristol Myers Squibb’s Opdivo for use before and after surgery for non-small cell lung cancer. A regimen ...
As the nights draw in Bryony Fernandez is preparing for the next phase of helping her fiancé, Jon Ward, to access the ...
Investor's Business Daily on MSN12h
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Health New Zealand's latest report shows encouraging improvements in cancer treatment wait times, emergency department ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback